Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Other Financing

Other Financing at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$8M+14.3%
Eli Lilly logo
Eli LillyLLY
-$591M+13.8%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's other financing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's other financing?
Supernus Pharmaceuticals (SUPN) reported other financing of $0 in Q1 2026.
How has Supernus Pharmaceuticals's other financing changed year-over-year?
Supernus Pharmaceuticals's other financing decreased by 100.0% year-over-year, from $20.1M to $0.
What does other financing mean?
Miscellaneous financing cash flows not classified in specific line items.